Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients

Selena Y. Lin 1, Ting-Tsung Chang 2*, Jamin D. Steffen 1, Sitong Chen 1, Surbhi Jain 1, Wei Song 1, Yih-Jyh Lin 3,* and Ying-Hsiu Su 4,*

Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. The beta-catenin gene, CTNNB1, is among the most frequently mutated in HCC tissues. However, mutational analysis of HCC tumors is hampered by the difficulty of obtaining tissue samples using traditional biopsy. Here, we explored the feasibility of detecting tumor-derived CTNNB1 mutations in cell-free DNA (cfDNA) extracted from the urine of HCC patients. Using a short amplicon qPCR assay targeting HCC mutational hotspot CTNNB1 codons 32–37 (exon 3), we detected CTNNB1 mutations in 25% (18/73) of HCC tissues and 24% (15/62) of pre-operative HCC urine samples in two independent cohorts. Among the CTNNB1-mutation-positive patients with available matched pre- and post-operative urine (n = 13), nine showed apparent elimination (n = 7) or severalfold reduction (n = 2) of the mutation in urine following tumor resection. Four of the seven patients with undetectable mutations in postoperative urine remained recurrence-free within five years after surgery. In contrast, all six patients with mutation-positive in post-operative urine recurred, including the two with reduced mutation levels. This is the first report of association between the presence of CTNNB1 mutations in pre- and post-operative urine cfDNA and HCC recurrence with implications for minimum residual disease detection.

Keywords: hepatocellular carcinoma; cell-free DNA; beta-catenin; urine; mutation; recurrence

1. Introduction

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide. The presence of HCC tumor-derived mutations in urine cell-free DNA (cfDNA) can serve as a non-invasive biomarker for disease detection and precision management [1,2]. Ample evidence exists that the Wnt/beta-catenin pathway plays a pivotal role in HCC development [3,4]. In particular, numerous mutations in the beta-catenin gene, CTNNB1, have been associated with HCC [5,6]. Patients with mutations in CTNNB1 and other Wnt/beta-catenin pathway genes typically show reduced responses to both kinase inhibitors [7] and immunotherapy [8]. Somatic CTNNB1 variants have therefore been proposed as potential markers for HCC detection [9] and therapeutic response monitoring [10–13]. Noninvasive detection of CTNNB1 variants in urine would greatly facilitate the development of a test for detection of minimum residual disease after treatment and for monitoring primary and recurrence HCC.

The annual HCC recurrence rate after surgery exceeds 10% and reaches 80% after five years [14–16]. Previous studies have shown that early recurrence of HCC is associated with low survival [17,18]. Thus, it is critical to identify patients at high risk of...
recurrence as early as possible. At present, no specific biochemical or genetic markers for HCC recurrence are in clinical use, with most postoperative patients monitored using serum alpha-fetoprotein (AFP) measurements and imaging tests such as computed tomography and MRI. Early detection of tumor-derived CTNNB1 mutations in urine cfDNA requires an assay, not only with high sensitivity, but with short amplicon size, as we have demonstrated previously [19]. In this study, a short amplicon (53 bp) qPCR assay targeting HCC-associated hotspot CTNNB1 exon 3 mutations in codon 32–37 was used for mutation detection in urine cfDNA from patients with HCC and to investigate the feasibility of using urine DNA markers as a prognostic marker for HCC recurrence and for detecting minimum residual disease after treatment. Our results demonstrate that the presence of detectable CTNNB1 mutations in both pre- and post-operative urine could be an indication of the presence of minimum residual disease and poor prognosis.

2. Materials and Methods
2.1. Construction of CTNNB1 S37C Plasmid

The CTNNB1 exon 3 region (NCBI Genbank no. AY463360; nt 27,007–27,219) was amplified from Hep3B cell genomic DNA by PCR (forward primer: 5'-CTGATTTGATGGAGTTGG-3'; reverse primer: 5'-CTGATTTGATGGAGTTGG-3'), end-polished, and blunt-end-ligated into the vector using the Agilent PCR-Script Amp(+) Cloning kit (Agilent Technologies, Santa Clara, CA, USA). Site-directed mutagenesis was performed using forward (5'-CTGGAATCCATTGTGGTGCCACTAC-3') and reverse (5'-GTAGTGGCACCACAATGGA TTCCAG-3') primers to generate the exon 3 S37C (hg19 chr3:41,266,113C>G) mutant plasmid, pCTNNB1-S37C. The plasmid sequence was verified by Sanger sequencing (data not shown).

2.2. Study Subjects and Samples

All samples, tissue (cohort 1) and urine (cohort 2), used in this study were obtained with informed consent from the National Cheng Kung University Hospital, Taiwan, in accordance with the guidelines of the Institutional Review Board. Information pertaining to each cohort is listed in Table 1 (cohort 1) and Table 2 (cohort 2). Note, cohort 1 and cohort 2 are two independent study populations. HCC is characterized by AJCC (TNM) staging and pathological grade 1 for well differentiated, grade 2 for moderate differentiated, grade 3 for poor differentiated, and grade 4 for undifferentiated as noted in each table.

Table 1. Clinicopathological characteristics of the cohort 1 tissue DNA * analyzed in this study.

| Diagnosis | Hepatitis (n = 35) | Cirrhosis (n = 35) | HCC (n = 73) |
|-----------|--------------------|--------------------|-------------|
| Mean age ± SD years | 54 ± 12 | 56 ± 14 | 60 ± 12 |
| Gender (Male:Female:Unknown) | 17:18:0 | 23:12:0 | 45:20:8 |
| Etiology | | | |
| HBV | 3 | 6 | 31 |
| HCV | 22 | 17 | 19 |
| HBV/HCV | 9 | 12 | 2 |
| Other | 0 | 0 | 14 |
| Unknown | 1 | 0 | 7 |
| Stage * | NA | NA | 19 |
| 1 | | | 31 |
| 2 | | | 12 |
| 3 | | | 11 |
Table 1. Cont.

| Diagnosis | Hepatitis \((n = 35)\) | Cirrhosis \((n = 35)\) | HCC \((n = 73)\) |
|-----------|----------------------|----------------------|------------------|
| Grade #   | NA                   | NA                   |                  |
| 1         |                      | 9                    |
| 2         |                      | 41                   |
| 3         |                      | 15                   |
| Unknown   |                      | 8                    |
| Tumor size, mean ± SD, cm | NA | NA | 5.0±3.3 |
| AFP level, ng/mL | NA | NA | 28 |
| ≤20       |                      |                      |
| >20       |                      | 37                   |
| Unknown   |                      | 8                    |

* Tissue DNA was isolated from tissue sections of the surgical resected FFPE tissue; †, AJCC (TNM) staging; ‡; pathological grading for differentiation; AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SD, standard deviation; NA, not applicable.

Table 2. Clinicopathological characteristics of the cohort 2 patient urine samples analyzed in this study.

| Diagnosis | HCC \((n = 62)\) |
|-----------|------------------|
| Mean age ± SD years | 59.9 ± 11.4 |
| Gender (Male:Female) | 44:18 |
| Etiology | |
| HBV | 30 |
| HCV | 15 |
| HBV/HCV | 1 |
| Other | 10 |
| Unknown | 6 |
| Stage * | |
| 1 | 18 |
| 2 | 28 |
| 3 | 12 |
| 4 | 2 |
| Unknown | 2 |
| Grade # | |
| 1 | 8 |
| 2 | 38 |
| 3 | 14 |
| Unknown | 2 |
| Tumor size, mean ± SD, cm | 5.26 ± 3.27 |
| AFP level, ng/mL | |
| ≤20 | 38 |
| >20 | 24 |
| Unknown | 0 |

* AJCC (TNM) staging; † pathological grading for differentiation; AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SD, standard deviation.

2.3. Tissue DNA Isolation and Quantitation

DNA from paraffin-embedded tissue sections was isolated using the MasterPure DNA kit (Epicenter, Madison, WI, USA), according to the manufacturer’s instructions. The concentration of liver tissue DNA was determined by a real-time PCR assay targeting the beta-globin gene, as previously described [20].
2.4. Urine Collection and DNA Isolation and Fractionation

Urine collection and DNA isolation were carried out as described previously [20]. Briefly, 0.5 M EDTA, pH 8.0, was added to a fresh urine sample to a final concentration of 10 mmol/L to inhibit possible nuclease activity, and the preserved sample was stored at −70 °C until DNA Isolation.

To isolate total urine DNA, the frozen urine sample was thawed at room temperature and mixed with an equal volume of 6 mol/L guanidine thiocyanate by inverting the tube eight times. Then, 1 mL of resin (Wizard DNA purification kit; Promega, Madison, WI, USA) was added to the urine lysate, and the sample was incubated with gentle mixing for two hours to overnight at room temperature. The resin-DNA complex was pelleted by centrifugation, transferred to a mini-column (provided in the kit), and washed with a buffer provided by the manufacturer. The DNA was then eluted with Tris-EDTA buffer. DNA less than 1 kb, designated as low molecular weight (LMW) urine DNA, was obtained from total urine DNA using carboxylated magnetic beads (Beckman Coulter, Indianapolis, IN) as previously described [21].

2.5. Detection of CTNNB1 Codon 32–37 Hotspot Mutations

Mutations in codons 32–37 (hg19 chr3:41,266,097-41,266,114) of exon 3 of the CTNNB1 gene were detected by the CTNNB1 32–37 mutation 53 bp qPCR assay developed by (JBS Science, Inc., Doylestown, PA, USA) according to the manufacturer’s protocol. The 18 bp CTNNB1 BNA NC[NMe] clamp was purchased from Biosynthesis, Inc. (Lewisville, TX, USA). To evaluate assay performance, serial dilutions of pCTNNB1-S37C were used, ranging from 1 to 10,000 copies per reaction. 1500 genome copies of wild-type (WT) human genomic DNA (Roche Applied Science, Indianapolis, IN, USA) were used as negative controls. Standards were prepared by spiking mutant plasmid in a background of WT DNA.

2.6. Sanger Sequencing

Isolated tissue DNA (1 ng) was amplified in a PCR reaction using 0.5 μM primers (forward: 5′-CTGATTGTGAGTTGG-3′, reverse: 5′-GAGTGAGAGACTGAGAAA-3′), 200 μM dNTPs, and HotStart Taq Plus polymerase (Qiagen, Valencia, CA, USA) in PCR buffer. The thermocycling program was as follows: 95 °C for 5 min to activate the polymerase, then 40 cycles at 95 °C for 30 s, 54 °C for 30 s, and 72 °C for 30 s, followed by a final extension at 72 °C for 4 min.

For sequencing of PCR products generated in the presence of the BNA NC[NMe] clamp, tissue DNA (2 ng) was amplified in a PCR reaction using the primers contained in the CTNNB1 32–37 mutation qPCR assay along with the CTNNB1 BNA NC[NMe] clamp. To increase the size of the amplified PCR product so that it is suitable for Sanger sequencing, a second round of PCR was performed using oligos containing an artificial tag sequence (forward: 5′-TCGTCGGCGCTACATCGAGATGTGTATAAGAGACAG-3′; reverse: 5′-GTCTCGTGGGAGGATTGATTGATGTTGATGTTACC-3′). Sanger sequencing was performed in both directions (forward primer: 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3′; reverse primer: 5′-GTCTCGTGGGAGGATTGATTGATGTTGATGTTACC-3′). All PCR products were purified using the Zymo DNA Cleanup and Concentration Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer’s instructions, and sent to the NAPCore Facility (CHOP, Philadelphia, PA, USA) for sequencing.

3. Results

3.1. Detection of CTNNB1 Hotspot Mutations in HCC and Non-HCC Tissues

Literature analysis revealed that approximately 90% of CTNNB1 mutations in HCC occur in two hotspot regions, codons 32–37 and 41–45, accounting for 55% and 34% of all CTNNB1 mutations in HCC, respectively, as detailed in Supplemental Table 1 and summarized in Figure 1. A short amplicon (53 bp) qPCR assay targeting the major hotspot region, encompassed by codons 32–37 was chosen for mutation detection in urine cfDNA. We
first determined the sensitivity of the assay by using varying amounts of pCTNNB1-S37C plasmid, as detailed in Materials and Methods, spiked into a background of 1000 copies of sonicated WT human genomic DNA containing no mutations in the CTNNB1 target region. The assay contained a sensitivity of 0.3% variant allele frequency (VAF) for CTNNB1 codon 32–37 mutations and a linearity range of 3–10⁴ copies of mutated DNA (Supplemental Figure S1).

**Figure 1.** CTNNB1 exon 3 mutational frequency in HCC. Data from several studies that sequenced CTNNB1 exon 3 in patients with HCC were compiled (see Supplemental Table S1). In nearly 90% of all HCC tumors with a mutation in CTNNB1, the mutation resides within one of two hotspot regions: region 1 (codons 32–37; 54.6%) and region 2 (codons 41–45; 34.3%). The X-axis denotes the codon number and amino acid encoded by it. The box linked to an amino acid lists the reported missense mutations within the codon and the corresponding amino acid changes.

Next, we determined the accuracy of CTNNB1 32–37 qPCR assay by detecting mutations in liver tissue DNA from patients with hepatitis (n = 35), cirrhosis (n = 35), or HCC (n = 73) and validating by Sanger sequencing. Sociodemographic and clinicopathological characteristics of these patients are presented in Table 1. Of the 73 HCC samples tested, 24.6% (n = 18) contained a detectable mutation (Figure 2A), consistent with the reported detection rate of 20–25% [22,23]. HCC-adjacent tissues from the 18 CTNNB1-mutation-positive patients contained no detectable mutations, suggesting that the CTNNB1 mutations detected in the tumor tissues were somatic rather than germline. None of the hepatitis or cirrhosis samples tested contained a detectable mutation at a limit of detection (LOD) of 10 copies/3 ng DNA. Thus, the CTNNB1 32–37 hotspot mutation rate was significantly higher in HCC than non-HCC liver tissue (p < 0.001, Chi-square test).
2) by the CTNNB1 assay and detected mutations in 24.1% (n = 15) of the patients. For 13 of these 15 patients, urine samples collected both before and after surgical resection of the tumor were available. Urine had been collected a day prior to surgery and then again at a follow-up visit (Table 3). Seven of the patients whose urine DNA contained CTNNB1 mutations before surgery showed no detectable mutations after surgery. Among them was patient U13, who had the highest mutant copy number before surgery, indicating that the

Figure 2. Analysis of CTNNB1 mutations in tissue samples from patients with different liver diseases. (A) CTNNB1 hotspot mutant allele frequencies obtained by the CTNNB1 32–37 mutation qPCR assay in liver tissues of patients with HCC, hepatitis, or cirrhosis. In the HCC subset (n = 73), 18 patients tested positive, while all of the hepatitis (n = 35) and cirrhosis (n = 35) samples tested negative. ***, p < 0.001. (B) Validation of the CTNNB1 32–37 mutation qPCR assay by Sanger sequencing. Five samples identified as positive by the qPCR assay with mutation frequencies of >15% were evaluated by Sanger sequencing. Of these five samples, three had detectable CTNNB1 mutations. When Sanger sequencing was repeated after enrichment for the mutation using the BNA\textsuperscript{NC}[NMe] clamp (see Materials and Methods) included in the PCR amplification reaction, CTNNB1 mutations in the other two samples were also confirmed. The right panel shows Sanger sequencing chromatograms with and without BNA\textsuperscript{NC}[NMe] enrichment. The mutation position is shaded in gray.

By PCR-Sanger sequencing analysis in 5 HCC tissue samples with >15% CTNNB1 32–37 VAF, the CTNNB1 mutations were verified in 3 of the 5 samples, A10K, A48K, and A38K (Figure 2B). To increase the sensitivity of the method, we re-sequenced the samples with the BNA\textsuperscript{NC}[NMe] clamp (see Materials and Methods) included in the PCR amplification before sequencing. This approach confirmed the mutations in the remaining two samples, A64K and A65K (Figure 2C). We then randomly selected 23 HCC tissues negative for CTNNB1 mutation for PCR-Sanger sequencing analysis. All 23 were found to contain only WT sequences in the region analyzed (Supplemental Figure S2).

3.2. Detection of CTNNB1 Hotspot Mutations in Urine of HCC Patients

Upon validation of the CTNNB1 32–37 qPCR assay for detection of hotspot mutations in tissue DNA, we screened for CTNNB1 32–37 mutations in urine cfDNA of HCC patients. We screened a total of 62 HCC urine samples from a second, independent cohort (Table 2) by the CTNNB1 assay and detected mutations in 24.1% (n = 15) of the patients. For 13 of these 15 patients, urine samples collected both before and after surgical resection of the tumor were available. Urine had been collected a day prior to surgery and then again at a follow-up visit (Table 3). Seven of the patients whose urine DNA contained CTNNB1 mutations before surgery showed no detectable mutations after surgery. Among them was patient U13, who had the highest mutant copy number before surgery, indicating that the

| Sample ID | % Mutant Copies | Sequencing (-BNA) | Sequencing (+BNA) |
|-----------|-----------------|------------------|------------------|
| A64K      | 79.4            | ND               | C/T 33           |
| A10K      | 48.4            | C/T 33           | C/T 33           |
| A48K      | 46.7            | ND               | C/T 33           |
| A65K      | 22.4            | A/T 32           | A/T 32           |
| A38K      | 15.8            | C/G 33           | C/G 33           |

ND, not detected.
CTNNB1 mutation detected in this patient’s preoperative urine was likely derived from the resected tumor. However, the other six patients remained positive for the CTNNB1 mutation after surgery. Analysis of clinical follow-up records revealed that all 6 of these patients developed HCC recurrence within five years post-resection. One of these patients, U3, was diagnosed with lung metastasis slightly less than a year after surgery. Only four patients (31%, 4/13) were negative for recurrence at five years, and all four were also negative for CTNNB1 hotspot mutations in postoperative urine. The overall sensitivity and specificity of the post-resection assay as a predictor of recurrence in this group of patients were 0.67 and 1.00, respectively.

### Table 3. Detection of CTNNB1 hotspot mutations in urine of HCC patients before and after tumor resection.

| Sample ID | Serum AFP (ng/mL) | Tumor | CTNNB1 32-37 Mutation (Copies per mL of Urine) | Urine Collection Post-Tumor Resection (Months) | Recurrence |
|-----------|------------------|-------|---------------------------------------------|---------------------------------------------|------------|
|           |                  | Stage | Grade | Size (cm) Before Resection | After Resection | Detected | Months Post-Resection |
| U1        | 6.9              | 1     | G2    | 1.9 | 2–20 | ND | 10 | No | NA |
| U2        | 5.0              | 1     | G2    | 3.5 | 2–20 | 29 | 3 | Yes | 26 |
| U3        | 19.1             | 2     | G3    | 14.5 | 2–20 | 881 | 3 | Yes | 21 |
| U4        | 1.8              | 3A    | G2    | 8.0 | 2–20 | 23 | 2 | Yes | 21 |
| U5        | 11.7             | 2     | G3    | 4.4 | 2–20 | 2–20 | 2 | Yes | 21 |
| U6        | 6.5              | 3A    | G2    | 3.5 | 21 | ND | 2 | No | NA |
| U7        | NT               | 2     | G2    | 1.5 | 24 | ND | 10 | Yes | 21 |
| U8        | 3.8              | 1     | G2    | 1.5 | 29 | ND | 2 | No | NA |
| U9        | 610.0            | 2     | G2    | 3.0 | 39 | ND | 1 | Yes | 4 |
| U10       | 4.0              | 1     | G1    | 2.0 | 42 | ND | 3 | No | NA |
| U11       | <1.5             | 3C    | G3    | 6.0 | 101 | 34 | 2 | Yes | 10 |
| U12       | NT               | 1     | G2    | 4.0 | 142 | 26 | 1 | Yes | 47 |
| U13       | 4.3              | 3A    | G3    | 5.0 | 498 | ND | 1 | Yes | 57 |

Recurrence was monitored for five years after surgery and detected by CT scan or MRI; *AJCC (TNM) staging; #pathological grading for differentiation; NT, not tested; ND, not detected; NA, not applicable; †average of two experiments.

### 4. Discussion

Using a short-amplicon qPCR assay, we demonstrated for the first time, the detection of CTNNB1 mutations in urine of HCC patients, and the prognostic utility of mutated CTNNB1 in postoperative urine for HCC patients whose urine contained such mutations before surgery. Together, our findings, consistent with our previous reports [19,20,24,25] show that urine can serve as a source of tumor-derived cfDNA for noninvasive mutation detection in patients with HCC. In our patient cohorts, we detected CTNNB1 mutations in tissue (25%) and urine (24%) samples at frequencies consistent with previous estimates of CTNNB1 mutation frequency in HCC [26–30].

Compared with blood and tissue, the use of urine for detecting HCC mutations holds three major advantages: (1) urine is easy to collect in large volumes, (2) its collection does not require trained clinical personnel, and (3) the procedure is entirely noninvasive and can be repeated as frequently as necessary. However, compared with plasma cfDNA, urinary cfDNA is even more fragmented [31]. To overcome this, short-amplicon (<60 bp) PCR-based assays are needed for detection of specific mutations in highly fragmented cfDNA [19,20,32]. The ability to detect CTNNB1 hotspot mutations in urine of HCC patients undergoing curative surgery may also contribute substantially to HCC precision medicine. CTNNB1 has recently emerged as a potential biomarker to identify immunotherapy responders and non-responders [8,33]. The utility of detecting CTNNB1 mutations in HCC therapy guidance remains to be evaluated.

Our study has several limitations. The number of HCC patients positive for CTNNB1 mutations before resection for whom a postoperative urine sample was also available was small (n = 13). Nevertheless, six of these patients were shown to retain detectable levels of CTNNB1 mutations after surgery, and all 6 developed HCC recurrence. However, 3 of the 7 patients negative for CTNNB1 mutations in postoperative urine did recur within 5 years. These observations may indicate that even higher sensitivity is needed to detect the low postoperative levels of CTNNB1 mutations in some HCC patients. Alternatively,
new tumors may arise independently of the original malignancy, a frequently reported complication in patients with HCC [34,35]. Another limitation is that the assay does not distinguish among different mutations in the target region. It is therefore possible that some of the patients shown to be positive after surgery had a different variant prior to it. The possibility of the assay detecting some mutations adjacent to the codon 32–37 region also cannot be ruled out.

Taken together, our results (1) demonstrate the feasibility of detection of HCC-derived mutations in the CTNNB1 gene in urine cfDNA, (2) provide evidence of association between the presence of CTNNB1 mutations in urine and the presence of minimal residual disease or HCC recurrence, and (3) warrant a further study for the application of urinary CTNNB1 mutation analysis in HCC precision medicine/disease management. Larger, multi-center studies of the correlation between CTNNB1 mutations in urine cfDNA and HCC tumor status are needed to evaluate the potential clinical utility of urinary CTNNB1 mutation detection in liver cancer management and precision medicine.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/diagnostics11081475/s1, Table S1. Frequency of CTNNB1 mutation in exon 3, Figure S1. Amplification curves of spiked-in standards and controls in the BNA NC [NMe] clamp-mediated CTNNB1 32–37 mutation qPCR assay, Figure S2. DNA sequencing of HCC tissue samples negative for CTNNB1 mutation.

Author Contributions: Study design, S.Y.L., J.D.S., S.J. and Y.-H.S.; Performed experiments, J.D.S., S.C. and S.Y.L.; Data analysis, S.Y.L., J.D.S., T.-T.C., Y.-J.L., W.S., S.J. and Y.-H.S.; Sample collection, T.-T.C. and Y.-J.L. Writing—original draft, S.Y.L., J.D.S. and Y.-H.S. Manuscript review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Institutes of Health R44 CA165312 (S.Y.L.) R01 CA202769 (Y.-H.S.).

Institutional Review Board Statement: The study received ethics approval from Heartland institutional review board (171201-173) on 12 January 2017.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All relevant data can be found in the manuscript and the supplementary file.

Acknowledgments: We thank Dmitry Goryunov and Shelby Schleyer for the support in proofreading and editing of this manuscript.

Conflicts of Interest: S.L., S.J., J.D.S. and S.C. are employees of JBS Science, Inc. W.S., S.L. and S.J. are stockholders of JBS Science, Inc. Y.-H.S. has received funding from JBS Science, Inc. T.-T.C. and Y.-J.L. declare no conflict of interest.

References
1. Schwarzenbach, H.; Hoon, D.S.; Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11, 426–437. [CrossRef] [PubMed]
2. Su, Y.-H.; Kim, A.K.; Jain, S. Liquid biopsies for hepatocellular carcinoma. Transl. Res. 2018, 201, 84–97. [CrossRef] [PubMed]
3. Cui, Y.; Wu, X.; Lin, C.; Zhang, X.; Ye, L.; Ren, L.; Chen, M.; Yang, M.; Li, Y.; Li, M.; et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway. Oncogene 2019, 38, 5516–5529. [CrossRef] [PubMed]
4. Li, M.; Mu, X.D.; Song, J.R.; Zhai, P.T.; Cheng, Y.; Le, Y.; Li, Z.B. PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma. Cell Cycle 2021, 20, 1010–1020. [CrossRef]
5. Lee, J.S. The mutational landscape of hepatocellular carcinoma. Clin. Mol. Hepatol. 2015, 21, 220–229. [CrossRef]
6. Shibata, T. Genomic landscape of hepatocarcinogenesis. J. Hum. Genet. 2021. [CrossRef]
7. Teufel, M.; Seidel, H.; Köchert, K.; Meinhardt, G.; Finn, R.S.; Llovet, J.M.; Bruix, J. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology 2019, 156, 1731–1741. [CrossRef] [PubMed]
8. Harding, J.J.; Nandakumar, S.; Armenia, J.; Khalil, D.N.; Albano, M.; Ly, M.; Shia, J.; Hechtman, J.F.; Kundra, R.; El Dika, I. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 2019, 25, 2116–2126. [CrossRef]
9. Su, Y.H.; Lin, S.Y.; Song, W.; Jain, S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev. Mol. Diagn. 2014, 14, 803–817. [CrossRef]

10. Delgado, E.; Okabe, H.; Preziosi, M.; Russell, J.O.; Alvarado, T.F.; Oertel, M.; Nejak-Bowen, K.N.; Zhang, Y.; Monga, S.P. Complete response of Ctnnb1-mutated tumours to beta-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J. Hepatol. 2015, 62, 380–387. [CrossRef]

11. Lachenmayer, A.; Alsinet, C.; Savic, R.; Cabellos, J.; Toffanin, S.; Hoshida, Y.; Villanueva, A.; Minguiez, B.; Newell, P.; Tsai, H.W.; et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 2012, 18, 4997–5007. [CrossRef] [PubMed]

12. Ashihara, E.; Takada, T.; Maekawa, T. Targeting the canonical Wnt/β-catenin pathway in hematological malignancies. Cancer Sci. 2015, 106, 665–671. [CrossRef] [PubMed]

13. Thakur, R.; Mishra, D.P. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J. Cell. Mol. Med. 2013, 17, 449–456. [CrossRef] [PubMed]

14. Portolani, N.; Coniglio, A.; Ghidoni, S.; Giovanelli, M.; Benetti, A.; Tiberio, G.A.; Giuliani, S.M. Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann. Surg. 2006, 243, 229–235. [CrossRef]

15. Shah, S.A.; Cleary, S.P.; Wei, A.C.; Yang, I.; Taylor, B.R.; Hemming, A.W.; Langer, B.; Grant, D.R.; Greig, P.D.; Gallinger, S. Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery 2007, 141, 330–339. [CrossRef] [PubMed]

16. Sherman, M. Recurrence of hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 2045–2047. [CrossRef]

17. Takeishi, K.; Maeda, T.; Tsujita, E.; Yamashita, Y.; Harada, N.; Itoh, S.; Harimoto, N.; Ikegami, T.; Yoshizumi, T.; Shirabe, K.; et al. Predictors of intrahepatic multiple recurrences after curative hepatectomy for hepatocellular carcinoma. Anticancer Res. 2015, 35, 3061–3066. [PubMed]

18. Shah, S.A.; Greig, P.D.; Gallinger, S.; Cattral, M.S.; Dixon, E.; Kim, R.D.; Taylor, B.R.; Grant, D.R.; Vollmer, C.M. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J. Am. Coll. Surg. 2006, 202, 275–283. [CrossRef] [PubMed]

19. Song, B.P.; Jain, S.; Lin, S.Y.; Chen, Q.; Block, T.M.; Song, W.; Brenner, D.E.; Su, Y.-H. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J. Mol. Diagn. 2012, 14, 112–119. [CrossRef] [PubMed]

20. Lin, S.Y.; Dhillon, V.; Jain, S.; Chang, T.-T.; Hu, C.-T.; Lin, Y.-J.; Chen, S.-H.; Chang, K.-C.; Song, W.; Yu, L. A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J. Mol. Diagn. 2011, 13, 474–484. [CrossRef] [PubMed]

21. Su, Y.H.; Song, J.; Wang, Z.; Wang, X.H.; Wang, M.; Brenner, D.E.; Block, T.M. Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann. N. Y. Acad. Sci. 2008, 1137, 82–91. [CrossRef] [PubMed]

22. Tornesello, M.L.; Buonaguro, L.; Tatangelo, F.; Botti, G.; Izzo, F.; Buonaguro, F.M. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 2013, 102, 74–83. [CrossRef]

23. Ally, A.; Balasundaram, M.; Carlsem, R.; Chuah, E.; Clarke, A.; Dhalla, N.; Holt, R.A.; Jones, S.J.; Lee, D.; Ma, Y. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017, 169, 1327–1341. [CrossRef] [PubMed]

24. Hann, H.-W.; Jain, S.; Park, G.; Steffen, J.D.; Song, W.; Su, Y.-H. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res. 2017, 3, 105–111. [CrossRef] [PubMed]

25. Jain, S.; Xie, L.; Boldbaatar, B.; Lin, S.Y.; Hamilton, J.P.; Meltzer, S.J.; Chen, S.-H.; Hu, C.-T.; Block, T.M.; Song, W.; et al. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatol. Res. 2014, 45, 1110–1123. [CrossRef] [PubMed]

26. Ikeda, S.; Lim, J.S.; Kurzrock, R. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: Implications for targeted therapeutics. Mol. Cancer Ther. 2018, 17, 1114–1122. [CrossRef]

27. Ikeda, S.; Tsigeln, I.F.; Skjervik, Å.A.; Kono, Y.; Mendler, M.; Kuo, A.; Sickleck, J.K.; Heestrand, G.; Banks, K.C.; Talasaz, A. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncol. 2018, 23, 586–593. [CrossRef] [PubMed]

28. Huong, A.; Zhang, X.; Zhou, S.-L.; Cao, Y.; Huang, X.-W.; Fan, J.; Yang, X.-R.; Zhou, J. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J. Cancer 2016, 7, 1907–1914. [CrossRef]

29. Liao, W.; Yang, H.; Xu, H.; Wang, Y.; Ge, P.; Ren, J.; Xu, W.; Lu, X.; Sang, X.; Zhong, S. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 2016, 7, 40481–40490. [CrossRef]

30. Wang, J.; Huang, A.; Wang, Y.-P.; Yin, Y.; Fu, P.-Y.; Zhang, X.; Zhou, J. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma. Ann. Transl. Med. 2020, 8, 237–249. [CrossRef] [PubMed]

31. Lin, S.Y.; Luo, Y.; Marshall, M.M.; Johnson, B.J.; Park, S.R.; Wang, Z.; Su, Y.-H. A New Method for improving extraction efficiency and purity of urine and plasma cell-free DNA. Diagnostics 2021, 11, 650. [CrossRef] [PubMed]

32. Su, Y.-H.; Wang, M.; Brenner, D.E.; Norton, P.A.; Block, T.M. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann. N. Y. Acad. Sci. 2008, 1137, 197–206. [CrossRef] [PubMed]
33. De Galarreta, M.R.; Bresnahan, E.; Molina-Sánchez, P.; Lindblad, K.E.; Maier, B.; Sia, D.; Puigvehi, M.; Miguela, V.; Casanova-Acebes, M.; Dhainaut, M. β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma. *Cancer Discov.* 2019, 9, 1124–1141. [CrossRef] [PubMed]

34. Jelic, S.; Sotiropoulos, G.C.; the ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 2010, 21, v59–v64. [CrossRef]

35. Xue, R.; Li, R.; Guo, H.; Guo, L.; Su, Z.; Ni, X.; Qi, L.; Zhang, T.; Li, Q.; Zhang, Z.; et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. *Gastroenterology* 2015, 150, 998–1008. [CrossRef] [PubMed]